Understanding Adverse Event Reporting Without the Jargon

Adverse event reporting is one of the most important parts of drug safety, but the terminology around it, things like ICSRs, expedited reporting and causality assessment, can feel dense if you are new to the field. This post breaks the process down in plain language, starting from how an adverse event report is first received, whether from a patient, doctor or through a clinical trial, through to how it gets assessed for seriousness and expectedness. We also explain why reporting timelines are so strict, since regulators use this data to catch safety signals early across an entire patient population rather than just one case. By the end you should have a working understanding of the process even without a formal pharmacovigilance background.